Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.38 |
| ▸ | RAF1 | P04049 | 5/20 | 0.38 |
| ▸ | KRAS | P01116 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.37 |
| ▸ | CASP1 | P29466 | 5/20 | 0.37 |
| ▸ | CASP7 | P55210 | 5/20 | 0.37 |
| ▸ | USP2 | O75604 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052205 | 0.93 | BRAF (0.43) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5054582 | 0.93 | BRAF (0.40) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5062822 | 0.92 | BRAF (0.40) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5056310 | 0.91 | BRAF (0.40) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5055255 | 0.91 | RAF1 (0.47) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5060258 | 0.90 | BRAF (0.42) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5055264 | 0.89 | BRAF (0.39) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL4553311 | 0.88 | BRAF (0.41) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5056538 | 0.88 | BRAF (0.42) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5062245 | 0.88 | BRAF (0.40) | BRAFRAF1KRASKDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | BRAF 2/4885RAF1 55/4885KRAS 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.